🚀 VC round data is live in beta, check it out!
Embecta Valuation Multiples
Discover revenue and EBITDA valuation multiples for Embecta and similar public comparables like Salus, Gerresheimer, Cerus, Arjo and more.
Embecta Overview
About Embecta
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
Founded
2021
HQ
Employees
1.9K
Website
Sectors
Financials (LTM)
EV
$2B
Embecta Financials
Embecta reported last 12-month revenue of $1B and EBITDA of $402M.
In the same LTM period, Embecta generated $679M in gross profit, $402M in EBITDA, and $124M in net income.
Revenue (LTM)
Embecta P&L
In the most recent fiscal year, Embecta reported revenue of $1B and EBITDA of $415M.
Embecta expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $679M | XXX | $677M | XXX | XXX | XXX |
| Gross Margin | 63% | XXX | 63% | XXX | XXX | XXX |
| EBITDA | $402M | XXX | $415M | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | 38% | XXX | XXX | XXX |
| EBIT Margin | 30% | XXX | 31% | XXX | XXX | XXX |
| Net Profit | $124M | XXX | $95M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 9% | XXX | XXX | XXX |
| Net Debt | — | — | $1B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Embecta Stock Performance
Embecta has current market cap of $592M, and enterprise value of $2B.
Market Cap Evolution
Embecta's stock price is $9.99.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $592M | 0.0% | XXX | XXX | XXX | $1.61 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEmbecta Valuation Multiples
Embecta trades at 1.7x EV/Revenue multiple, and 4.4x EV/EBITDA.
EV / Revenue (LTM)
Embecta Financial Valuation Multiples
As of March 28, 2026, Embecta has market cap of $592M and EV of $2B.
Equity research analysts estimate Embecta's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Embecta has a P/E ratio of 4.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $592M | XXX | $592M | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | 4.4x | XXX | 4.3x | XXX | XXX | XXX |
| EV/EBIT | 5.5x | XXX | 5.3x | XXX | XXX | XXX |
| EV/Gross Profit | 2.6x | XXX | 2.6x | XXX | XXX | XXX |
| P/E | 4.8x | XXX | 6.2x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 9.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Embecta Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Embecta Margins & Growth Rates
Embecta's revenue in the last 12 month declined by (0%).
Embecta's revenue per employee in the last FY averaged $0.6M.
Embecta's rule of 40 is 37% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Embecta's rule of X is 36% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Embecta Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (0%) | XXX | (1%) | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | 38% | XXX | XXX | XXX |
| EBITDA Growth | (4%) | XXX | (7%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 37% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 36% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3% | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 35% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Embecta Public Comps
See public comps and valuation multiples for other Medical Supplies comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Salus | XXX | XXX | XXX | XXX | XXX | XXX |
| Gerresheimer | XXX | XXX | XXX | XXX | XXX | XXX |
| Cerus | XXX | XXX | XXX | XXX | XXX | XXX |
| Arjo | XXX | XXX | XXX | XXX | XXX | XXX |
| Universal Vision | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Embecta M&A Activity
Embecta acquired XXX companies to date.
Last acquisition by Embecta was on XXXXXXXX, XXXXX. Embecta acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Embecta
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialEmbecta Investment Activity
Embecta invested in XXX companies to date.
Embecta made its latest investment on XXXXXXXX, XXXXX. Embecta invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Embecta
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Embecta
| When was Embecta founded? | Embecta was founded in 2021. |
| Where is Embecta headquartered? | Embecta is headquartered in United States. |
| How many employees does Embecta have? | As of today, Embecta has over 1K employees. |
| Who is the CEO of Embecta? | Embecta's CEO is Devdatt Kurdikar. |
| Is Embecta publicly listed? | Yes, Embecta is a public company listed on Nasdaq. |
| What is the stock symbol of Embecta? | Embecta trades under EMBC ticker. |
| When did Embecta go public? | Embecta went public in 2022. |
| Who are competitors of Embecta? | Embecta main competitors are Salus, Gerresheimer, Cerus, Arjo. |
| What is the current market cap of Embecta? | Embecta's current market cap is $592M. |
| What is the current revenue of Embecta? | Embecta's last 12 months revenue is $1B. |
| What is the current revenue growth of Embecta? | Embecta revenue growth (NTM/LTM) is (0%). |
| What is the current EV/Revenue multiple of Embecta? | Current revenue multiple of Embecta is 1.7x. |
| Is Embecta profitable? | Yes, Embecta is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Embecta? | Embecta's last 12 months EBITDA is $402M. |
| What is Embecta's EBITDA margin? | Embecta's last 12 months EBITDA margin is 37%. |
| What is the current EV/EBITDA multiple of Embecta? | Current EBITDA multiple of Embecta is 4.4x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.